Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) [Phase 2]

View source ↗

Summary

Phase 2 trial to evaluate the safety and tolerability of subcutaneous Efgartigimod PH20 given by prefilled syringe in kidney transplant recipients with antibody…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• Efgartigimod PH20 SC (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Antibody-mediated Rejection | Phase 2 | Status: RECRUITING